Oncology

59% of these patients treated with Tagrisso plus chemotherapy had complete brain tumour responses in FLAURA2 Phase III trial.

Imfinzi reduced the risk of disease progression or death by 29% vs. chemotherapy. First Phase III trial to demonstrate clinical benefit of immunotherapy plus PARP inhibition in advanced or recurrent endometrial cancer.

Trial will continue to assess primary endpoint of event-free survival.

At AstraZeneca, we have the ambition to redefine the backbone of current cancer treatment – chemotherapy and radiotherapy regimens – with our discovery platform that delivers highly targeted antibody-drug conjugates (ADCs) and radioconjugates directly into cancer cells.

Decision based on FLAURA2 Phase III trial results which extended median progression-free survival by nearly 9 months versus standard of care.

Immuno-oncology has grown exponentially over the last decade and is transforming outcomes for patients.

AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its robust portfolio and pipeline at the European Society for Medical Oncology (ESMO) Congress, 20 to 24 October 2023.

Cell therapy in oncology has been spearheaded by the development of therapeutic chimeric antigen receptor (CAR)‑T cells, created by isolating and modifying a patient’s T cells to target their cancer.